Method for prevention and treatment of dangerous neuroviral infections

FIELD: medicine.

SUBSTANCE: for treatment of dangerous neuroviral infections, mice are injected with Moliksan® in a single dose of 20.0 mg/kg of body weight immediately after infection and after 24, 48, 72 hours.

EFFECT: increased effectiveness of combating diseases caused by pathogens of dangerous neuroviral infections.

6 tbl

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to organic chemistry, namely to benzimidazole-4-carboxamide derivatives of formula , wherein X means an alkenyl group C2-C7 substituted by two methyls, nitro-radical mono-substituted thienyl, unsubstituted quinolinyl, unsubstituted indolyl, unsubstituted pyridazinyl, unsubstituted piperazinyl, C1-C6-alkyl disubstituted piperazinyl, unsubstituted piperidinyl, unsubstituted pyrazinyl, unsubstituted imidazolyl, unsubstituted pyrimidinyl, phenyl monosubstituted pyrimidinyl, pyrimidinyl disubstituted by an amine radical and a radical specified in a group containing -F, -Cl, -Br or -I, hydroxyl trisubstituted phenyl, methoxy-radical trisubstituted phenyl, hydroxyl and methoxy-radical disubstituted phenyl, pyrazolyl disubstituted by a radical specified in a group containing a C1-C6-alkyl, and by a radical specified in a group containing -F, -C1, -Br or -I; Y means aminophenyl monosubstituted by a radical of -F, -O, -Br or -I phenyl, hydroxyethyl disubstituted by hydroxymethyl or C1-C6-alkyl and phenyl monosubstituted by a nitro group, an amino group or a halogen atom; Y also means unsubstituted piperazinyl, unsubstituted pyridyl, unsubstituted pyrazinyl, C1-C6-alkyl monosubstituted thiazol, unsubstituted pyrimidinyl, unsubstituted purinyl. The invention also refers to a pharmaceutical composition based on the compound of formula (I), using the compound of formula (I), a method for producing the compound of formula (I).

EFFECT: there are prepared new benzimidazol-4-carboxamide derivatives possessing antiviral activity.

5 cl, 6 dwg, 4 tbl, 688 ex

FIELD: medicine.

SUBSTANCE: invention represents an oral anti-enteroviral and immunostimulant agent in the form of capsules containing interferon and additives, differing by the fact that a therapeutic substance is human recombinant interferon alpha-2b immobilised on polyethylene glycol, having a molecular weight of 1.5 kD by a physical method of binding by an accelerated electron flow in a dose of 1.5 Mrad. The ingredients in the agent are taken in a certain ratio.

EFFECT: extending the range of anti-enteroviral agents possessing immunostimulant properties.

6 ex, 10 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine and concerns using rhCC10 protein for preparing a therapeutic agent for the therapeutic or preventive effect on influenza virus.

EFFECT: invention provides reducing a pulmonary titre of influenza virus.

11 cl, 4 dwg, 1 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmacology, in particular, to medication, possessing antiviral, antimicrobial, immunomodulating and anti-inflammatory action, in form of drops, spray, gel and solution for injection for treatment and prevention of infection diseases: herpes, acute respiratory viral infections, hepatitis, HIV-infections, viral disease. Medication according to invention contains complex of cytokines with Trilonum B, immobilised on biologically compatible polymer as carrier.

EFFECT: obtaining medication, possessing antiviral, antimicrobial, immunomodulating and anti-inflammatory action.

3 cl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to 5,5-condensed heteroarylene compounds IIIB, where U2, V1, V2 and W1 are selected from O, N, NH, S or CR3a; U1, W2, X1 and X2 represent C or N; R1 and R2 represents hydrogen, -C(O)CH(NR1bR1c)R1a, -C(O)CH(N(R1c)C(O)OR1b)R1a or -C(O)OR1a; R3a represents hydrogen or R3; R3 represents halogen or -C(O)OR1a; L1 and L2 are such as given in invention formula, each Z1 and Z2 represents bond or -O-; each Rla, R1b and R1c represents hydrogen, C1-6 alkyl or C6-14 aryl; or Rlb and Rlc together with N atom, which they are bound to, form 5-6-membered heterocyclyl; q, r, s, t and u equal 1. Invention also relates to pharmaceutical compositions, containing 5,5-condensed heteroarylene compounds, and methods of treating or preventing HCV infection.

EFFECT: 5,5-condensed heteroarylene derivatives, possessing inhibiting activity with respect to hepatitis C virus.

43 cl, 42 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a novel compound - N,N-bis(1-adamantyl-1-ethylamine) hydrochloride of the structural formula I and a method for production thereof. Compound has biological activity and can be used as a component of a medicinal agent or as an impurity label of a medicinal agent as a standard sample in analytical chemistry of pharmaceutical preparations. A method of producing a compound of formula I includes a) obtaining 1-adamantyl-1-ethylamine from 1-adamantyl-1-ethylamine hydrochloride, b) obtaining a Schiff base of structural formula III by treating with a compound obtained at step (a) with acetyl adamantane, c) treating the Schiff base of formula III with a reducing agent to obtain bis(1-adamantyl-1-ethylamine) hydrochloride of formula I. The compound is characterised by a boiling point, IR, NMR and a mass spectrum data.

EFFECT: improved method.

2 cl, 8 dwg, 1 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to N-adamantylbenzotriazole derivatives

and where R1 and R2 are hydrogen or a nitro group. The invention also relates to a method of producing the compound of formulae 1 and 2.

EFFECT: obtaining novel N-adamantylbenzotriazole derivatives which exhibit anti-influenza A virus activity.

3 cl, 5 ex

FIELD: medicine.

SUBSTANCE: drops possessing antiviral and immunomodulatory effects characterised by the fact that they represent a 95% ethanol infusion of wild strawberry leaves and fruit specified in: red raspberry fruit, mountain ash fruit, bilberry fruit, blood-red hawthorn fruit, cinnamon rose fruit; 15-25 mg of the substance in 1 ml of the infusion.

EFFECT: drops possess pronounced antiviral and immunomodulatory effects.

15 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: method includes treating crushed Echinacea purpurea (L.) Moench roots and rhizome with steam, extraction with ethyl alcohol, then steeping, stirring, steeping, draining a portion of the extract which is equal to the amount of the loaded Echinacea purpurea (L.) Moench roots and rhizome, after draining a portion of the extract, adding ethyl alcohol to the treated material, draining the whole extract; extracting crushed Echinacea purpurea (L.) Moench herbs with ethyl alcohol, steeping, then stirring, steeping, draining a portion of the extract which is equal to the amount of the loaded Echinacea purpurea (L.) Moench herbs, after draining a portion of the extract, adding ethyl alcohol to the treated herbs, draining the whole extract; all obtained extracts are mixed, cooled and filtered under certain conditions. An Echinacea purpurea (L.) Moench tincture. Use of the method to obtain an Echinacea purpurea (L.) Moench tincture.

EFFECT: method preserves the biological activity of components of the tincture and medicinal properties.

3 cl

FIELD: medicine.

SUBSTANCE: invention represents an encapsulated liposomal antiviral agent based on human interferon alpha-2b for vaginal application, characterised by the fact that each capsule is made in the form of a hollow coating, which encloses a powder excipient and liposomes distributed in the excipient, and sodium alginate, a water-soluble polymer gel former; the excipient consists of lactose, sodium chloride, 12-aqueous disodium hydrogen phosphate and sodium dihydrogen phosphate, whereas each of the liposomes represents a hollow coating containing lecithin, cholesterol and alpha-tocopherol, and a nucleus inside the coating and containing recombinant human interferon alpha-2; the ingredients of the agents are taken in a certain ratio, mg.

EFFECT: maintaining the storage activity of recombinant human interferon alpha-2 and prolonged action in vaginal application.

2 cl, 3 dwg, 6 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: vitamins A and E, novocaine blocades of parotid salivary glands, intake of potassium iodide solution, intake of galantamine, additionally administered is "Vezugen" in a dose of 2 tablets (capsules) 2 times per day for 30 days are administered.

EFFECT: invention makes it possible to stimulate the formation of own saliva in patients in case of drug sialoadenopathy, conditioned by chemotherapy of malignant tumours.

2 ex

FIELD: medicine.

SUBSTANCE: skin regeneration is stimulated by using a synthetic analogue of indolicidine, a natural antimicrobial peptide having formula H-Lys-Lys-Pro-Trp-Lys-Trp-Pro-Lys-Lys-Pro-Trp-Arg-Arg-NH2.

EFFECT: accelerating reparative skin regeneration following a burn injury.

2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology, more specifically to MUC1 cytoplasmic domain peptides, and can be used in the anticancer therapy. A method for inhibiting MUC1-positive cancer cell in an individual involves administering into an individual the MUC1-peptide of the length of at least 6 sequential MUC1 residues and no more than 20 sequential MUC1residues and containing the sequence CQCRRK, wherein the amino terminal cysteine from CQCRRK is closed at its NH2 terminal by at least one amino acid residue, which shall not conform with the native transmembrane sequence MUC-1. Alternatively, there can be used MUC-1 peptide of the length of at least sequential MUC1 residues and no more than 20 sequential MUC1 residues, which contains the sequence CQCRRK with all amino acid residues of the above peptide being D-amino acids.

EFFECT: invention enables inhibiting MUC1oligomerisation effectively and inducing the tumour cell apoptosis and the tumour tissue necrosis in vivo.

80 cl, 16 dwg, 1 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention represents method of preparing viscoelastic protector of corneal endothelium, including dissolution of initial therapeutic component with excessive viscosity in phosphate buffer, filtration and sterilisation until required viscosity value is obtained, characterized by the fact that as initial therapeutic component used is 3% solution of native hyaluronic acid, after dissolution 1% peptide complex, consisting of amino acid desmosine and following short-chained peptides-oligopeptides: GlyTrpIle; IleAspIle; PheArgPro; GlnHisHis; ProHisTyr; ThrTrpTrp; LysPheThr; LysArgMet; PheCysMet; IleIle; AspLysLys; TrpPro; GluThr, is introduced, and sterilisation is carried out by ionizing radiation in the range of radioactive radiation from 78×107 Mrad to 11×108 Mrad.

EFFECT: recovery of biochemical processes in endothelial layer of cornea with constant eye cornea moistening and increase of biocompatibility, which contributes to fast rehabilitation after traumas or surgery.

2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: presented solutions relate to field of immunology. Claimed are: pharmaceutical, containing peptide, obtained from HIG2 or URLC10, capable of inducing cytotoxic T-lymphocytes (CTL) by formation of antigen-presenting complex with antigen HLA-A0206. Described are isolated antigen-presenting cell and CTL and methods for their induction. Antigen-presenting cell is induced by contact of cell, expressing antigen HLA-A0206, with peptide, obtained from HIG2 or URLC10. Cytotoxic lymphocyte is induced by contact of CD8-positive T-cell with antigen-presenting cell, presenting on its surface complex of antigen HLA-A0206 and peptide, obtained from HIG2 or URLC10. Characterised are method and means of immune anti-tumour response induction by introduction to patient of medication, which contains peptide, capable of inducing CTL.

EFFECT: claimed inventions can be used in treatment of cancer disease, characterised by higher expression of HIG2 or URLC10.

12 cl, 8 dwg

FIELD: medicine.

SUBSTANCE: 30-60 minutes after the following fraction of radical irradiation on the 1st, 3rd and 5th day of each week for the whole period of irradiation, the preparation Molixan® 60 mg (2 ml) is introduced intramuscularly to the patient.

EFFECT: higher efficacy and safety of the chemotherapy ensured by relieving the manifestations of oral mucositis.

4 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to compositions and methods for prevention or treatment of renal fibrosis in an individual. Particularly, the method for prevention or treatment of renal fibrosis in an individual involves administering a composition containing a pharmaceutically effective amount of a vasoactive intestinal peptide (VIP) or one or more functional VIP fragments specified in VIP(10-28), VIP(4-12), VIP(4-16), VIP(4-20), VIP(4-24), VIP(6-10), VIP(6-12), VIP(6-16), VIP(6-20), VIP(6-24) or conventional substitutes thereof into the individual exposed to a risk of developing renal fibrosis or suffering from renal fibrosis.

EFFECT: using the group of invention enables preventing or delaying developing renal fibrosis in the individual more effectively.

15 cl, 4 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: conduit wall is presented by a material of random micro- and nanofibres of a bioresorptive polymer of poly(ε-caprolactone), and the content is presented by a self-assembled nanostructured hydrogel of acetyl-(Arg-Ala-Asp-Ala)4-CONH2(PuraMatrix™) oligopeptide. The above conduit is implanted in a complex with the direct local delivery of vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2) genes to be introduced into the proximal and distal nerve segments, while the formed conduit is implanted into a nerve rupture, and its ends are fixed with epineural sutures.

EFFECT: invention provides a stimulating effect on the invasion of regenerative medullated fibres, on the recovery of motor and sensitive nerve function, and enables improving the effect of the recovery of the nerve structure and function after the extended ruptures.

4 cl

FIELD: chemistry.

SUBSTANCE: invention relates to biochemistry and biotechnology and can be used in the pharmaceutical industry to produce drugs for treating conditions, which involves inhibiting dipeptidyl peptidase IV (DPPIV). Proposed is use of the disclosed inhibitors as a means of suppressing the function of DIPPIV through direct administration thereof and as part of a pharmaceutical composition.

EFFECT: obtaining a group of novel peptides, having DIPPIV inhibitor properties, which enable to reduce enzyme activity by at least 25%.

9 cl, 1 tbl, 11 dwg, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a peptide capable of binding with scurfin and inhibiting biological activity of scurfin, which is selected from a peptide consisting of an amino acid sequence Arg-Asp-Phe-Gln-Ser-Phe-Arg-Lys-Met- Trp-Pro-Phe-Phe-X, where X is absent or X is present and represents X14 or X14-X15, where X14 and X15 independently denote an amino acid, a version of said peptide and a pharmaceutically acceptable salt thereof. The invention also discloses a fused protein and a pharmaceutical composition, which involves use of said peptide and fused protein, as well as use thereof to produce and treat pathologies which require transient regulation or inhibition of immunosuppressive activity of regulatory T lymphocytes, such as a neoplastic disease or infectious disease. The invention also relates to a method of producing said peptide and fused protein, including a protein or peptide coding nucleic acid, a DNA construct, an expression vector and a host cell.

EFFECT: invention provides effective treatment of infectious and neoplastic diseases which require transient regulation or inhibition of immunosuppressive activity of regulatory T lymphocytes.

26 cl, 10 dwg, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely represents composition, which contains mixture of particles of hydrophobic silicon dioxide aerogel, which have specific area of surface per weight unit (Sw) in range from 500 to 1500 m2/g and size, expressed in form of volume mean diameter (D[0.5]), in range from 1 to 1500 mcm, and at least one first linear silicone oil, which has viscosity higher than 50 mm2/s, and at least second and third linear silicone oils, and each of them has viscosity lower than or equal 50 mm2/s.

EFFECT: mixture of particles of silicon dioxide aerogel and linear oils provides possibility of obtaining compositions, which provide comfort and smoothness of skin after application and have dullness and "soft focus"-adding properties.

23 cl, 8 ex

Up!